Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch

Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.

Perrigo Company PLC’s been waiting for a Food and Drug Administration advisory panel’s vote on recommending approval for the first OTC switch of an oral contraceptive in the US since it acquired HRA Pharma a year ago.

The Dublin-based firm now will have to wait as long as another three months learn whether HRA will have approval...